These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 25194106)
21. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881 [TBL] [Abstract][Full Text] [Related]
22. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526 [TBL] [Abstract][Full Text] [Related]
23. Chronic genitourinary and gastrointestinal toxicity of prostate cancer patients undergoing pelvic radiotherapy with intensity-modulated versus 4-field technique. Su AW; Jani AB Am J Clin Oncol; 2007 Jun; 30(3):215-9. PubMed ID: 17551295 [TBL] [Abstract][Full Text] [Related]
24. Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus. Kalakota K; Liauw SL Urology; 2013 Jun; 81(6):1196-201. PubMed ID: 23540863 [TBL] [Abstract][Full Text] [Related]
25. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity. Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Thomas G; Kiss A; Mamedov A; Deabreu A Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):898-905. PubMed ID: 21237581 [TBL] [Abstract][Full Text] [Related]
26. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity. Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838 [TBL] [Abstract][Full Text] [Related]
27. Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes. Kotecha R; Djemil T; Tendulkar RD; Reddy CA; Thousand RA; Vassil A; Stovsky M; Berglund RK; Klein EA; Stephans KL Int J Radiat Oncol Biol Phys; 2016 Jul; 95(3):960-964. PubMed ID: 27302511 [TBL] [Abstract][Full Text] [Related]
28. Dose-adapted salvage radiotherapy after radical prostatectomy based on an erMRI target definition model: toxicity analysis. Zilli T; Jorcano S; Peguret N; Caparrotti F; Hidalgo A; Khan HG; Vees H; Weber DC; Miralbell R Acta Oncol; 2014 Jan; 53(1):96-102. PubMed ID: 24032443 [TBL] [Abstract][Full Text] [Related]
29. Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer. Karlsdóttir A; Johannessen DC; Muren LP; Wentzel-Larsen T; Dahl O Radiother Oncol; 2004 Apr; 71(1):43-53. PubMed ID: 15066295 [TBL] [Abstract][Full Text] [Related]
30. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial. Viani GA; Viana BS; Martin JE; Rossi BT; Zuliani G; Stefano EJ Cancer; 2016 Jul; 122(13):2004-11. PubMed ID: 27028170 [TBL] [Abstract][Full Text] [Related]
31. Helical tomotherapy for prostate cancer radiation therapy: An audit of early toxicity and quality of life. Kunheri B; Lakshmi JS; Ravindran GC; Haridas ; Marwaha V J Cancer Res Ther; 2021; 17(2):366-371. PubMed ID: 34121678 [TBL] [Abstract][Full Text] [Related]
32. Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients. Cozzarini C; Fiorino C; Deantoni C; Briganti A; Fodor A; La Macchia M; Noris Chiorda B; Rancoita PM; Suardi N; Zerbetto F; Calandrino R; Montorsi F; Di Muzio N Eur Urol; 2014 Dec; 66(6):1024-30. PubMed ID: 24985964 [TBL] [Abstract][Full Text] [Related]
33. Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy. Beck M; Wust P; Barelkowski T; Kaul D; Thieme AH; Wecker S; Wlodarczyk W; Budach V; Ghadjar P Radiat Oncol; 2017 Aug; 12(1):125. PubMed ID: 28793907 [TBL] [Abstract][Full Text] [Related]
34. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients. Wortel RC; Incrocci L; Pos FJ; Lebesque JV; Witte MG; van der Heide UA; van Herk M; Heemsbergen WD Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):737-44. PubMed ID: 25752386 [TBL] [Abstract][Full Text] [Related]
35. Prospective evaluation of quality of life 54 months after high-dose intensity-modulated radiotherapy for localized prostate cancer. Goineau A; Marchand V; Rigaud J; Bourdin S; Rio E; Campion L; Bonnaud-Antignac A; Mahé MA; Supiot S Radiat Oncol; 2013 Mar; 8():53. PubMed ID: 23510499 [TBL] [Abstract][Full Text] [Related]
36. Fractionated high-dose-rate brachytherapy as monotherapy in prostate cancer: Does implant displacement and its correction influence acute and late toxicity? Aluwini S; Busser WM; Baartman LE; Bhawanie A; Alemayehu WG; Boormans JL; Kolkman-Deurloo IK Brachytherapy; 2016; 15(6):707-713. PubMed ID: 27364871 [TBL] [Abstract][Full Text] [Related]
37. Prostate cancer treated with image-guided helical TomoTherapy® and image-guided LINAC-IMRT : Correlation between high-dose bladder volume, margin reduction, and genitourinary toxicity. Drozdz S; Schwedas M; Salz H; Foller S; Wendt TG Strahlenther Onkol; 2016 Apr; 192(4):223-31. PubMed ID: 26742732 [TBL] [Abstract][Full Text] [Related]
38. Analysis of gastrointestinal and genitourinary morbidity of postoperative radiotherapy for pathologic T3 disease or positive surgical margins after radical prostatectomy using national cancer institute expanded common toxicity criteria. Choo R; Pearse M; Danjoux C; Gardner S; Morton G; Szumacher E; Loblaw DA; Cheung P Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):989-95. PubMed ID: 18436391 [TBL] [Abstract][Full Text] [Related]
39. Patterns and predictors of amelioration of genitourinary toxicity after high-dose intensity-modulated radiation therapy for localized prostate cancer: implications for defining postradiotherapy urinary toxicity. Ghadjar P; Jackson A; Spratt DE; Oh JH; Munck af Rosenschöld P; Kollmeier M; Yorke E; Hunt M; Deasy JO; Zelefsky MJ Eur Urol; 2013 Dec; 64(6):931-8. PubMed ID: 23522772 [TBL] [Abstract][Full Text] [Related]
40. Clinical and dosimetric predictors of acute toxicity after a 4-week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. Arcangeli S; Strigari L; Soete G; De Meerleer G; Gomellini S; Fonteyne V; Storme G; Arcangeli G Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):39-45. PubMed ID: 18538488 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]